News

Press Releases

Dec 5, 2022

Fractyl Health Announced Positive Proof-of-Concept Data of Pancreatic GLP-1 Gene Therapy in a Type 2 Diabetes Animal Model at the 20th World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease

POC efficacy data in rodents shows that a novel adeno-associated virus (AAV) pancreatic gene therapy platform can confer dose-dependent effects on improving insulin production and reducing blood sugar Dose-depend...

Nov 2, 2022

Fractyl Health Initiates Landmark Scientific Partnership to Study Root Cause Mechanisms Underlying Type 2 Diabetes

Newly formed Erase T2D task force comprises leading scientists and pioneering scientific research to elucidate the role of the duodenum in type 2 diabetes and metabolic control Fractyl Health-supported research pr...

May 22, 2022

Fractyl Health Presents New Mechanistic Data on Revita^® DMR in Type 2 Diabetes

Patients treated with Revita experienced a 0.8%-point reduction in HbA1c along with a 33% improvement in markers of insulin sensitivity three months after undergoing the procedure Markers of insulin production cap...

May 17, 2022

Fractyl Health to Present New Data on Revita^® DMR in Type 2 Diabetes at Digestive Disease Week 2022

Fractyl Health, an organ-editing metabolic therapeutics company focused on pioneering a new approach to the treatment of type 2 diabetes (T2D), will share new data in an oral presentation during the 2022 Digestive Diseas...

Apr 4, 2022

Fractyl Health Announces FDA IDE Approval to Begin Revitalize-2 Pivotal Study Designed for Patients with Type 2 Diabetes (T2D) Who Are Not Yet on Insulin

Revitalize-2 is the second pivotal study for the Revita DMR® system (Revita®) in Fractyl Health’s Revitalize T2D clinical development program Revitalize T2D is designed to evaluate the potential of Revita i...

Feb 8, 2022

Fractyl Health Receives Reimbursement Authorization in Germany for Revita DMR^® System

The Revita DMR System (Revita) gains reimbursement authorization from the German Institute for Hospital Remuneration (InEK) with a NUB Status 1 designation NUB Status 1 entitles participating hospitals in German...

Feb 1, 2022

Fractyl Health Publishes Two-Year Durability Data After a Single Revita DMR^® Therapeutic Procedure in Patients with Type 2 Diabetes

REVITA-1 was an open-label cohort study evaluating Revita® in patients with type 2 diabetes on oral anti-diabetic agents but not yet on insulin This is the first publication showing two-year durability of impro...

Jan 18, 2022

Fractyl Health Provides Initial Clinical Update on Open-Label REVITA-T2Di

Fractyl Health, an organ-editing metabolic therapeutics company focused on pioneering a new approach to the treatment of type 2 diabetes (T2D), announced today initial interim feasibility data from human clinical experie...

Jan 12, 2022

Fractyl Health Appoints Kelly Barnes to the Company’s Board of Directors

Fractyl Health, an organ editing metabolic therapeutics company focused on pioneering a new approach to the treatment of type 2 diabetes (T2D), today announced the appointment of Kelly Barnes to the company’s board of ...

Nov 30, 2021

Fractyl Health Announces the FDA’s Authorization of Expanding the Revitalize-1 Study’s Sample Size

LEXINGTON, Mass., November 30, 2021 - Fractyl Health, an organ-editing metabolic therapeutics company focused on pioneering a new approach to the treatment of type 2 diabetes (T2D), announced today the United States Food...

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Fractyl Health disavows any obligation to update the information contained in such press releases after the date of their issuance.

Media Contact: Nancye Green, Fractyl Health,
ngreen@fractyl.com, +1 (917) 273-3536